UNSPSC 51181917: Buserelin

This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C60H86N16O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PXW8U3YXDV, chemically known as luteinizing hormone-releasing hormone (pig), 6-(o-(1,1-dimethylethyl)-d-serine)-9-(n-ethyl-l-prolinamide)-10-deglycinamide- but generally known as buserelin, which bears US NIH Compound Identifier 42615. Buserelin most often comes in base and acetate forms.

UNSPSC 51181917 Buserelin is a Commodity code representing specific pharmaceutical products procured by state and local health systems and cooperative purchasing alliances. State and local governments buying under this code source branded and generic pharmaceuticals through multistate cooperative agreements that establish master contracts with manufacturers, requiring NDC-specific pricing, cGMP and FDA compliance, and distribution through authorized wholesale channels. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances that aggregate demand across participating state agencies, local health departments, and other public health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary active buyer in recent solicitations, using cooperative mechanisms to negotiate volume pricing and standardize supplier requirements across member jurisdictions.

The code shows recent activity centered in the Upper Midwest and Pacific Northwest, with MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) identifying participating states including Minnesota and Oregon. MMCAP solicited manufacturers to supply products meeting specific NDC codes through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contract terms effective July 1, 2026 and running two years for new respondents. Evaluation weighted price competitiveness at 75 percent, with remaining points distributed across fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must maintain commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and must certify cGMP compliance and Drug Supply Chain Security Act adherence.